AC
AVIR icon

Almitas Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Almitas Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-445,386
Closed -$1.6M – 69
2025
Q2 		$1.6M Sell
445,386
-269,619
-38% -$804K 0.4% 37
2025
Q1 		$2.14M Sell
715,005
-36,998
-5% -$115K 0.71% 28
2024
Q4 		$2.52M Sell
752,003
-632,526
-46% -$2.1M 0.55% 30
2024
Q3 		$4.64M Buy
1,384,529
+94,342
+7% +$342K 1.64% 17
2024
Q2 		$4.27M Buy
+1,290,187
New +$4.81M 1.78% 13

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almitas Capital's AVIR Position: Q3 2025 in Review

Almitas Capital sold out of Atea Pharmaceuticals (AVIR) in Q3 2025, closing a stake of 445,386 shares — an estimated $1.6M sold.

Almitas Capital first reported a position in AVIR in Q2 2024 and held it in 5 quarters. The position peaked at $4.64M in Q3 2024. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

  • Almitas Capital reported no remaining Atea Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Almitas Capital sold 445,386 Atea Pharmaceuticals shares in Q3 2025, an estimated $1.6M.
  • Almitas Capital first reported a position in Atea Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Almitas Capital's Atea Pharmaceuticals position peaked at $4.64M in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Almitas Capital's 13F filing for Q3 2025, filed 14 Nov 2025.